TABLE 1.

Incidence, latency, and molecular and histological analysis of virus-induced tumors (series A)

SL3-3 virus	Tumor incidence (no. of mice with tumor development/no. injected)	Mean tumor latency (no. of days ± SD)	Histopathologya	Clonal DNA rearrangementsb (no. of tumors with clonal rearrangements/no. investigated)		Complex enhancer changesc (no. of tumors with complex enhancer changes/no. examined)
				Igκe	TCRβ
wt	13/13	60 ± 9	Pre-TLLd	0/11	11/11	ND
mEa/s	24/24	58 ± 8	ND	0/11	11/11	0/24
3mGR	21/21	57 ± 6	Pre-TLL	0/11	11/11	0/21
3mGR+mEa/s	25/25	55 ± 9	ND	0/11	11/11	2/24
3mEgre	23/23	109 ± 44	Various types			13/23
	14/23	105 ± 35	Pre-TLL	0/14	14/14	12/14
	2/23	98 ± 0	PCT/Pre-TLL	2/2	2/2	0/2
	2/23	156 ± 55	PCT	ND	ND	0/2
	2/23	125 ± 134	ML w.M	0/2	0/2	0/2
	2/23	87 ± 16	ML wo.M	0/2	0/2	1/2
	1/23	111	PCT/MKL	1/1	ND	0/1
3mEgre+mEa/s	21/21	180 ± 41	Various types			12/21
	9/21	213 ± 15	PCT/STL	9/9	9/9f	5/9
	5/21	144 ± 41	Pre-TLL	3/5	4/5	3/5
	2/21	133 ± 18	PCT/Pre-TLL	1/2	2/2	1/1
	2/21	153 ± 49	PCT	2/2	1/2	1/2
	1/21	187	ML	1/1	1/1	0/1
	1/21	187	PCT/ML wo.M	1/1	0/1	1/1
	1/21	206	PCT/ML	0/1	0/1	0/1

^aTumor phenotypes were determined by histopathological examination. ML w.M, myeloid leukemia with maturation; ML wo.M, myeloid leukemia without maturation; ML, myeloid leukemia, not otherwise specified; MKL, megakaryoblastic leukemia; PCT, plasmacytomas; pre-TLL, preT-cell lymphoblastic lymphoma; STL, small T-cell lymphoma; and ND, not determined. Some animals developed tumors of mixed phenotypes (data not shown).

^bDetected by the Southern blot analysis of HindIII-digested genomic tumor DNA with TCRβ (J1 and J2) and Igκ light chain-specific probes.

^cComplex secondary enhancer changes found in virus-induced tumors by PCR analysis.

^dDiagnosed for another series of mice injected with wt SL3-3 at the same facility.

^eAll Igκ rearrangements were represented by very weak bands.

^fT-cell rearrangements observed in four of the nine cases were weak.